Please keep in mind I'm talking out of my butt here since I haven't done any research yet, but one might expect the incidence of anti-dMAb antibodies to be lower than exogenously administered antibodies because all the normal post-translational modifications are going to be in place and they are thus less likely to elicit an immune response.
Can someone help me understand, though, what the point of producing therapeutic proteins and antibodies endogenously is? Why bother, especially for therapeutic proteins?
News 
Market Data 
Discover 
